TG103 injections may be effective in achieving weight reduction in patients with obesity
1. In this randomized, double-blind, placebo-controlled trial, the use of once-weekly subcutaneous TG103 resulted in significant weight reduction at 12 ...
Tag: obesity
#VisualAbstract: Wireless Feedback System was Not Non-inferior to the Same System Plus Coaching in Achieving Weight Loss Goals
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Roche: CT-388 Dual GLP1-GIP Receptor Agonist Clinically Improves Weight Loss
Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to ...
#VisualAbstract: Semaglutide Improves Outcomes in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Click here to to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Eli Lilly: Tirzepatide Shows Promise In Treating Obstructive Sleep Apnea In Two Phase 3 Clinical Trials
Tirzepatide led to a 63% mean reduction in restricted/obstructed breathing events per hour in patients with moderate to severe obstructive ...
Semaglutide improves symptoms and function in obesity-related heart failure
1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer ...
Semaglutide improves obesity-related heart failure symptoms
1. In this randomized controlled trial, semaglutide was more effective in reducing heart failure-related symptoms and physical limitations in patients ...
Obesity may be a risk factor for stillbirth during pregnancy
1. Pregnant individuals with obesity according to their body mass index (BMI) had an increased risk for stillbirth when compared ...
The 2 Minute Medicine Podcast Episode 32
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...
Semaglutide improves cardiovascular outcomes in obese patients without diabetes
1. In this randomized-controlled trial, the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide reduced the risk of cardiovascular death, myocardial infarction, ...
